Mr James Armitage MD, FRCS (Urol)
James is a Consultant Urological Surgeon at Addenbrooke's hospital where he specialises in the management of patients with Kidney Cancer and Testis Cancer.
James completed his undergraduate medical training at Guys and St Thomas's Hospitals in London and completed his basic surgical training in Chichester. He then undertook a period of research at The Royal College of Surgeons of England that led to the award of MD. James went on to complete his higher surgical training in the East of England during which time he gained specialist experience at both the Norfolk and Norwich, and Addenbrooke's teaching hospitals.
He was recently elected as a member of the Executive Committee of the British Association of Surgeons Section of Oncology. James maintains a strong academic interest, publishing in high quality peer-reviewed clinical journals and presenting his research locally, nationally and internationally.
James is Honorary Senior Lecturer at both the University of Edinburgh and Anglia Ruskin universities where he is a tutor for their Urology Masters degrees. He is a member of the Joint Committee on Intercollegiate Examinations Urology Question Writing panel and is the Urology Specialty Trainee Lead at Addenbrooke’s hospital. He has organised and teaches on national and international training courses on Emergency Urology and laser prostate surgery, and he regularly teaches on the FRCS (Urol) revision course.
Outside work, James is a keen hockey player and golfer, and is kept busy by his three teenage sons.
Mr Thomas Mitchell MEng, DPhil, BMBCh, FRCS (Urol)
Tom is a Cancer Research UK and Royal College of Surgeons Clinician Scientist Fellow Honorary Consultant Urologist.
Tom began his medical training as a graduate in Oxford, prior to rotating through Junior Doctor roles in the Severn Deanery. His formal training in urology started in the East of England, at Addenbrooke's and the West Suffolk Hospital, finishing with the Kidney Cancer Fellowship at Addenbrooke's Hospital. He now works clinically as an Honorary Consultant, supported as a Clinician Scientist Fellow by Cancer Research UK and the Royal College of Surgeons.
Intermixed with his clinical development, he has a wide experience in academic research. This has ranged from formal qualification in Medical Engineering and device development, through to extensive genomic based investigations. focusing on understanding how cancers initiate, progress, and evade treatment.
His clinical interest centres around the surgical management of patients with renal cancer. He is closely involved in the portfolio of the renal oncological clinical trials that are established in Cambridge, using sequencing technologies to better understand the behaviour of these tumours.
Professor Grant Stewart BSc, MBChB, PhD Edin, MA Cantab, FRCSEd (Urol)
Professor Stewart is joint Programme lead of the Urological Malignancies Programme since early 2020, following his appointment as Professor of Surgical Oncology at the University of Cambridge. With over 150 peer reviewed publications and £52 million in research grants and clinical trial income, he is a global leader in renal cell cancer research and coordinates the a group of over 40 clinicians, translational researchers and basic scientists across the Cambridge Biomedical Campus with a shared interest in renal cell cancer research (CamRenCan). Clinically, Grant provides all modes of treatment for kidney cancer, from major open surgery to robotic minimally invasive approaches.
Prior to moving to Cambridge University, Professor Stewart was Senior Lecturer in Urological Surgery at the University of Edinburgh, where he led the Edinburgh Urological Cancer Group and developed and still co-directs the Scottish Collaboration on Translational Research into Renal Cell Cancer (SCOTRRCC) - a Scotland-wide kidney-cancer bio-repository of 1200 patients with high-quality clinical-data linkage. He also chairs the Scientific and Education Committee of The Urology Foundation, is a member of the Clinical Expert Review Panel of Cancer Research UK and is Chief Investigator for several renal-cancer clinical trials. Grant is a trustee of The Urology Foundation and Kidney Cancer UK, he is a section Editor of the British Journal of Urology International, member of Association of Academic European Urologists and Fellow of Selwyn College, Cambridge.
Dr Brent O'Carrigan BSc, MBBS, MMed, MRCP(UK), FRACP
Dr O'Carrigan is a Consultant Medical Oncologist at Addenbrooke's. He trained in London and Sydney, Australia, then completed a drug development early phase clinical trials fellowship at the Royal Marsden with Professor Johann de Bono. Dr. O'Carrigan got his PhD at the CRUK Cambridge Institute with Professor Carlos Caldas, with funding from the prestigious General Sir John Monash and Cambridge Trust International Scholarships. For his PhD in translational cancer research, Dr. O'Carrigan profiled the immune response with high-dimensional mass cytometry and the treatment response with ctNDA of patients with cancer.
His clinical interests are renal cancer and melanoma, translational research, drug development, clinical trials and novel trial designs.
Dr. O'Carrigan is a seasoned traveller; he's trekked in the Himalayas, camped in Kenya and Tanzania, scuba dived in Mozambique, and proposed to his now wife in Cambodia.
Professor Tim Eisen PhD, FRCP, FMedSci
Tim Eisen is the Global Franchise Head for GU Oncology in Roche Product Development and Professor of Medical Oncology at the University of Cambridge. He is particularly interested in working at the interface between sectors as he has broad experience at senior levels in academia, clinical practice, industry and in charities.
Tim trained at the Royal Marsden Hospital and took up the chair of medical oncology in Cambridge in 2006. He has published over 200 peer-reviewed articles with an h-index of 59 and a RG score of 48.5. He is the oncology editor of the Oxford Textbook of Medicine 6th edition. His 3 major research areas are the first study of a BRAF inhibitor in melanoma, the identification of genetic risk factors for lung cancer and the development of VEGFR receptor inhibitors as a new standard of care for patients with renal cell carcinoma. The Cambridge Kidney Cancer Service is now the largest in the UK with a research programme focused on the identification and curative treatment of early disease. In 2019, Tim was elected a Fellow of the Academy of Medical Sciences.
In 2014, Tim took part-time leave of absence from the University to work in AstraZeneca as it moved its research and Development Hub to the Cambridge Biomedical Campus. His main work was as the Vice President of AstraZeneca Oncology Early Clinical Development, leading a US and UK-based team of 150 people to design, deliver and analyse a portfolio of over 160 clinical trials of new AstraZeneca oncology drugs across the world.
In 2020, Tim moved to Roche to take up his current position as Global Franchise Head for GU Oncology. In this role, he has reorganised the Late Stage GU Oncology team into tumour teams to refresh the Roche Genentech late stage trials strategy in prostate, bladder and renal cancer.
Tim works with patient support charities, particularly Kidney Cancer UK and Macmillan Cancer Support, the largest UK charity supporting people affected by cancer. He led the Clinical Advisory Board for 10 years, alerting Macmillan Cancer Support to scientific and practical developments in oncology and became a trustee of the charity in 2006.
Dr Sarah Welsh BMChB, BSc, PhD, MRCP UK (Medical Oncology)
Dr Welsh is a Consultant in Medical Oncology with particular expertise in translational clinical trials and the use of immunotherapies in cancer, including drug combination trials, new small molecule and antibody therapies, management of toxicities relating to immunotherapy agents, development of pharmocodynamic and predictive biomarkers and novel clinical trials designs including Bayesian/ adaptive approaches . She has been joint Programme Lead in the Urological Malignancies Programme since the beginning of 2020. As well as her role as Principal Investigator on a number of academic and industry-sponsored clinical trials, Sarah is Chair of the Immunotoxicity Working Group, deputy Chair of the Oncology Clinic Management Group , a member of the Cambridge Renal Cancer Network, and leads the translational studies of a number of Cambridge-led clinical trials in Renal Cancer, Melanoma and Immunotoxicity.
With a special interest in the management of immunotherapy-induced toxicities, Dr Welsh has published over 40 peer-reviewed publications relating to cancer and its management and secured almost £500,000 of grant funding – most notably the MRC Clinical Academic Research Partnership Grant for the development and validation of a ‘humanised’ mouse model for renal cancer. After early clinical training in London at Imperial and University College London Hospitals, she was ranked #1 in the UK for entry into Medical Oncology training and completed her Medical Oncology training at the Cambridge University Hospitals NHS Trust, whilst also being awarded an Academic Clinical Lectureship at University of Cambridge. Her research program focused on exploiting novel pathways for the development of anti-cancer agents - particularly in renal cancer - and was based at Professor John Griffiths’ laboratory at the CRUK Cambridge Institute. In 2015 she undertook a further Fellowship at the Melanoma Institute Australia in Sydney to specialise in Melanoma and the role of the immune system in response to anti-cancer agents, focusing primarily on immunotherapies.
Professor Evis Sala MD, PhD, FRCR
Evis Sala is the Professor of Oncological Imaging at the University of Cambridge and co-leads the CRUK Cambridge Centre Advanced Cancer Imaging Programme and the Integrated Cancer Medicine Programme.
Professor Sala’s research focuses on the development and validation of functional imaging biomarkers to rapidly evaluate treatment response using physiologic and metabolic tumour habitat imaging. Her research in the field of radiogenomics has focused on understanding the molecular basis of cancer by demonstrating the phenotypic patterns which occur as a result of multiple genetic alterations that interact with the tumour microenvironment to drive the disease in several tumour types. Her work integrates quantitative imaging methods for evaluation of spatial and temporal tumour heterogeneity with genomics, proteomics and metabolomics. She is also leading multiple research projects focusing on the development and implementation of artificial intelligence methods for image reconstruction, segmentation, and data integration.
Professor Sala is an outstanding educator, orator and mentor. In recognition for her contribution to education and research in oncological imaging she received the Radiology Society of North America (RSNA) Honoured Educator Award in 2014, 2017 and 2020. Her leadership extends to the most important international bodies in the field, as Fellow of the International Cancer Imaging Society, Fellow of the International Society for Magnetic Resonance in Medicine and Fellow of the European Society of Urogenital Radiology.
Professor Sala played volleyball for the Albanian national under 21s team, she loves Latin dancing and modern art.
Dr Ines Horvat-Menih
Ines received her Doctor of Medicine degree from the Medical University of Vienna in 2020. During her studies she worked as a research assistant in the Neuroanaesthesia group which investigated the detection and differentiation of cerebral microemboli using TCD Ultrasound. She joined the Prostate Cancer group at the Department of Molecular Medicine of Aarhus University to conduct the research for her diploma thesis. She analysed the prognostic potential of a ratio model based on miRNA signatures from radical prostatectomy tissue samples and validated her results in laboratory setting. Her clinical training in oncology took place at the National Centre for Tumour (NCT) diseases in Heidelberg.
Ines was awarded several scholarships for academic excellence, most notably the Zois scholarship by the government of Slovenia and the Leistungsstipendium by the Medical University of Vienna. Her PhD research is supported by the CRUK studentship.
Her PhD project focuses on the hyperpolarised 13C-pyruvate MRI in renal cancer. Ines is involved in radiology site of WIRE clinical trial, while at the same time unravelling metabolic mechanisms underlying benign and malignant renal tumours.